The mission of NNECOS is to promote the highest quality care for patients with cancer and blood disorders in our region through professional networking, education, and scientific research, as well as patient advocacy and public policy.


Drug Shortages Sign On Letter

Lunchtime Best Oncology Practice Series

Upcoming Topics:

  • 4/25/24 - Empathy in Action: Integrating Emotional Responsiveness into Advance Care Planning Across Healthcare Disciplines - Hilary Carroll McGuire, DNP, FNP-BC, ACHPN
  • 5/30/24 - Social Determinants of Health - presented by Takeda 
  • 6/27/24 - Exercise to help with Fatigue - Jenny Spencer, BSN, RN, OCN

New Job Posted - NNECOS Classifieds

  • Dartmouth Cancer Center - NP or Physician Assistant - Per Diem

  • Dartmouth Cancer Center - NP or Physician Assistant

  • Dartmouth Cancer Center - Hematology Advanced Practice Provider

  • UVM Cancer Center - Faculty Scientist

  • UVM Cancer Center - 

    Medical oncologist/hematologist faculty member on the Clinical 

    Scholar Pathway at the Assistant/Associate level
  • UVM Cancer Center - 

    Physician-scientist/academic clinician to serve as Associate Director of Clinical &

    Translational Research.

  • Beth Israel Lahey Health Exeter -

    Experienced Hematology/Oncology Physician.
  • UVM Medical Center - Clinical Program Coordinator - Hematology 


Learn more about our unique funding program

Latest FDA Approvals And Drug-Related Updates

Latest FDA Approvals

  • April 5 - FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors
  • March 22 - FDA approves mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
  • March 19 - FDA grants accelerated approval to ponatinib with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
  • March 7 - FDA grants accelerated approval to zanubrutinib for relapsed or refractory follicular lymphoma
  • March 6 - FDA approves nivolumab in combination with cisplatin and gemcitabine for unresectable or metastatic urothelial carcinoma
  • March 6 -FDA approves inotuzumab ozogamicin for pediatric patients with acute lymphoblastic leukemia 
  • March 1 - FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications
  • February 16 - FDA approves osimertinib with chemotherapy for EGFR-mutated non-small cell lung cancer | FDA
  • February 16 - FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma | FDA
  • February 15 - FDA approves tepotinib for metastatic non-small cell lung cancer
  • February 13 - FDA approves irinotecan liposome for first-line treatment of metastatic pancreatic adenocarcinoma
  • January 19 - FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma
  • January 12 - FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 Stage III-IVA cervical cancer

Package/Label Updates

  • August - FDA approves new indication for  anemia without previous erythropoiesis stimulating agent use (ESAnaïve) in adult patients with very low-to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions

Code Updates

  • Effective for dates of service on or after April 1, 2024, the Centers for Medicare and Medicaid Services (CMS) has assigned the following Healthcare Common Procedure Coding System (HCPCS)* J-Code for ELREXFIO (elranatamab-bccm) injection:
J1323- Injection, elranatamab-bcmm, 1 mg

Other Updates

Business of Oncology Practice

Missed this series? Recording available

Looking Back!

Enjoy this wonderful interview with 3 of NNECOS' founding members!

Get Involved with a NNECOS Task Force



Thank You Corporate Members!

Group Practice Members

Because your entire team benefits
from being a part of NNECOS!

Regional Educational Programs

Special thanks to our 2024 Diamond & Platinum Corporate Members!





Platinum Members





View the complete list of corporate members.

Northern New England Clinical Oncology Society
P.O. Box 643
Sandown, NH 03873-0643
Telephone (603) 887-1948

This website brought to you by:

Powered by Wild Apricot Membership Software